Tenmile

🇦🇺 This Week in Australian Startups #180, 4th October 2026

Weekly roundup reporting Australian startup funding rounds and government grants, a venture fund close, agreed acquisitions, an IPO pricing, a collapse, plus executive hires and AI policy developments.

Skopos Bio raises $8.4M seed to advance radioactive cancer therapy

Melbourne oncology startup Skopos Bio has raised a seed round from Tenmile, Tin Alley Ventures and Yosemite to advance radioactive cancer therapy toward human trials.

Brandon Capital's $60m taypayer-funded biotech bets

Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.

Also australiatimes.com

Aravax Awarded FDA Fast Track Designation for PVX108

The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.

This Week in Australian Startups #174, 16th August 2026

Australian startups raised funds including Alloy Robotics, Farmbot and Atmo Biosciences. Firmus Technologies acquired Benmax while Tabcorp bought BetMakers. SafetyCulture rebranded to Mitti.

Eight ANZ startups that raised $67.4 million this week

Eight Australian and New Zealand startups secured a combined $67.4 million in funding across various sectors including agtech, medtech, robotics, and fintech.

Australia’s ADHD system made him ‘snap’. Now he’s raised millions to build a new one

Zac Altman’s ADHD telehealth startup Kantoko has secured $3.5 million in a Side Stage Ventures-led seed round, with Andrew Forrest’s Tenmile and Go1’s founders investing; the article also recalls his earlier ventures’ sales.

Also Dealroom·Startup Daily·Business News Australia·SmartCompany

Perx Health announces dual strategic transactions: Perx Australia to merge with Navigator Group; Clutch to Acquire Perx USA

Digital health firm Perx Health splits in two: Clutch has bought its US business and its Australian arm will combine with Navigator Group, with founders moving to roles at the buyers.

Also Dealroom

Cancer treatment biotech AdvanCell injects $178 million Series C

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.

Also Startup Daily·SmartCompany·Forbes Australia

Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy

Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.

Superseeder: psychedelic biotech Psylo plants $12 million in latest 'Seed' round

Psylo, a Sydney maker of psychedelic therapies, has landed a US$8 million seed round led by Tenmile while moving to the US; earlier raises in 2022 and 2021 are recalled.

Aravax Media Release

Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)

Harnessing the power of your mind

Profile of Mindset Health's founder brothers and their hypnotherapy apps, covering a fresh $18m Series A and earlier backing from Startmate and James Beshara.

Also Alberts Impact Ventures portfolio·SmartCompany·Crunchbase News

Andrew Forrest doubles down on therapeutic ecstasy biotech Emyria

Therapeutic psychedelics biotech Emyria has banked $2.5 million via a share placement co-led by Sixty Two Capital and Taylor Collison, with follow-on from Andrew Forrest's Tenmile, funding MDMA- and psilocybin-assisted therapy and cannabinoid trials.

Four Australian startups that raised $60.6 million this week

A weekly roundup reports four Australian companies together securing about $60 million: Unyoked, SpeeDx, Mutinex and Live Verdure, with funds earmarked for European and US expansion and product development.

Also SmartCompany·SmartCompany·SmartCompany

Andrew Forrest backs Sydney biotech startup in $26 million raise

Sydney diagnostics developer SpeeDx banked $26 million for American expansion, with $5 million from Andrew Forrest's new fund Tenmile and follow-on support from Platinum and Northpond.

Also SmartCompany

Billionaires Andrew and Nicola Forrest take aim at peanut allergy

Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.

Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily

Aravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile

Aravax has begun its Series B with a US$20 million investment from Brandon Capital and Tenmile, funding Phase 2 trials of its peanut allergy immunotherapy PVX108 while it seeks further capital.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Forbes Australia·Techboard·Business News Australia

Ignition Lane's Great Big Wrap: VCs court cash, an M&A bash & Canva makes a splash

Ignition Lane's weekly tech roundup covering fresh Australian startup raises, new venture funds and closes, a wave of acquisitions, delistings and a liquidation, executive moves, and Canva's product launch.

Also Techboard·Startup Daily

FUNDED August 2022

Techboard's monthly roundup tallies August 2022 private funding at $207m across 22 deals, listing the month's raises, BlackRock's acquisition of Akaysha Energy, One Click Life's reverse takeover listing, and several fund closes.

Also Startup Daily

Twiggy Forrest is backing biotech with a new $250 million VC fund

Andrew Forrest's private investment company Tattarang is launching Tenmile, a Perth-based $250 million health-tech venture fund that has already backed Emyria and Carina Biotech and partnered with Rock Health.